journal article·2012-03

In vitro drug release from chitosan/Cloisite 15A hydrogels

Anca Cojocariu, Lenuta Profire, Magdalena Aflori, Cornelia Vasile

Publisher page

Abstract

Abstract Chitosan biocomposite hydrogels were used as drug carriers for the delivery of some compounds with bronchodilatatory and anti-inflammatory activities. Chitosan nanocomposite hydrogels were prepared by crosslinking the chitosan nanocomposites with glutaraldehyde. The matrix was characterized by swelling experiments, X-ray diffraction and scanning electron microscopy. An intercalated structure was formed. The hydrogels were loaded with paracetamol, theophylline, two xanthine derivatives 7-[2-hydroxy-3-(4-acethyl-amino-phenoxy)-propyl]-8-R-1,3-dimethyl-xanthine derivatives with (R = H, NO2 for D1 and D2, respectively) and two corresponding novel nitric oxide donors compounds such as 7-[2-nitroxyacethyl-oxy-3-(4-acethyl-amino-phenoxy)-propyl]-8-R-1,3-dimethyl-xanthine (R = H, NO2 for 65 and respectively 77 compounds). Their controlled release was evaluated in acidic media (pH = 2.2) simulating the gastric fluid. The effect of Cloisite 15A addition on the drug release was determined. A higher concentration of 9 mass% Cloisite 15A significantly retarded the drug release. The kinetics of the drug release was studied in order to ascertain the type of release mechanism. Because the release of drugs from drug-intercalated montmorillonite was controllable, these new materials have a great potential as a delivery host in the pharmaceutical field.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Hydrogels: synthesis, properties, applications · Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (63)

Show source-provided references
1. Nanoclay reinforced fibers and nonwomens10.1177/155892500800300303 ↗
2. Biocompatibility Tests of Chitosan Hydrogels
3. Evaluation of mathematical models describing drug release from estradiol transdermal systems10.1081/DDC-120016687 ↗
4. Organosillicate–polymer drug delivery systems: controlled release and enhanced mechanical properties10.1016/S0168-3659(03)00133-0 ↗
5. Thermal characterization of some new xanthine derivatives10.1016/S0040-6031(99)00342-1 ↗
6. Interpolymer complexes of poly(acrylic acid) and chitosan: influence of the ionic hydrogel-forming medium10.1016/S0142-9612(02)00541-0 ↗
7. Cell proliferation and controlled drug release studies of nanohybrids based on chitosan-g-lactic acid and montmorillonite10.1016/j.actbio.2008.08.007 ↗
8. Poly (d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs10.1016/j.biomaterials.2005.03.021 ↗
9. Preparation, characterization, swelling and in vitro drug release behaviour of poly[N-acryloylglycine-chitosan] interpolymeric pH and thermally-responsive hydrogels10.1016/j.eurpolymj.2005.05.035 ↗
10. Release of cationic drugs from loaded clay minerals10.1007/s003960100527 ↗
11. Solubility of paracetamol in pure solvents10.1021/je990124v ↗
12. Preparation and diffusional evaluation of sustained — release suppositories containing ibuprofen microspheres
13. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol10.1016/S0378-5173(00)00494-4 ↗
14. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition10.2174/1874467210902010001 ↗
15. Rate of release of medicaments from ointment bases containing drugs in suspension10.1002/jps.2600501018 ↗
16. A pH-sensitive nanocomposite microsphere based on chitosan and montmorillonite with in vitro reduction of the burst release effect10.3109/03639041003677798 ↗
17. On the importance and mechanisms of burst release in matrix-controlled drug delivery system10.1016/S0168-3659(01)00248-6 ↗
18. Polymer nanocomposites for biomedical applications10.1557/mrs2007.235 ↗
19. Montmorillonite as a drug delivery system: intercalation and in vitro release of timolol maleate10.1016/j.ijpharm.2009.03.004 ↗
20. Intercalation and control release of vitamin B6 from montmorillonite-vitamin B6 hybrids10.1007/s00396-009-2067-3 ↗
21. A study of montmorillonite intercalated with vitamin B1 as drug carrier10.1016/j.clay.2009.06.001 ↗
22. Synthesis and characterization of a novel chitosan/montmorillonite/hydroxyapatite nanocomposite for bone tissue engineering10.1088/1748-6041/3/3/034122 ↗
23. Layered bionanocomposites as carrier for procainamide10.1016/j.ijpharm.2010.01.002 ↗
24. Biopolymer–clay hydrogel composites as drug carrier: host–guest intercalation and in vitro release study of lidocaine hydrochloride10.1016/j.clay.2011.03.017 ↗
25. Mechanism of solute release from porous hydrophilic polymers10.1016/0378-5173(83)90064-9 ↗
26. Oral sustained delivery of paracetamol from in situ-gelling gellan and sodium alginate formulations10.1016/S0378-5173(03)00163-7 ↗
27. Effect of bentonite on the physical properties and drug-release behavior of poly (AA-co-PEGMEA)/bentonite nanocomposite hydrogels for mucoadhesive10.1002/app.13499 ↗
28. Effect of montmorillonite on the swelling behavior and drug-release behavior of nanocomposite hydrogels10.1002/app.12624 ↗
29. Controlled delivery of a hydrophilic drug from a biodegradable microsphere system by supercritical anti-solvent precipitation technique10.1080/09687860600945552 ↗
30. The solubility of theophylline in aqueous amine solutions10.1002/jps.3030380212 ↗
31. Unique rheological behavior of chitosan-modified nanoclay at highly hydrated state10.1021/jp8107304 ↗
32. Hydrogels in controlled release formulations: network design and mathematical modeling10.1016/j.addr.2006.09.004 ↗
33. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier10.1016/S0142-9612(01)00325-8 ↗
34. Drug release behaviour of chitosan–montmorillonite nanocomposite hydrogels following electrostimulation10.1016/j.actbio.2008.01.012 ↗
35. Recent developments in nitric oxide donor drugs10.1038/sj.bjp.0707224 ↗
36. A comparative study of various microencapsulation techniques: effect of polymer viscosity on microcapsule characteristics
37. Chitosan–alginate composites blended with cloisite 30B as a novel drug delivery system for anticancer drug paclitaxel10.1007/s12588-011-9000-6 ↗
38. Loading and delivery of sertraline using inorganic micro and mesoporous materials10.1016/j.ejpb.2006.11.023 ↗
39. Dependence on the preparation procedure of polymorphism and crystallinity of chitosan membranes10.1271/bbb.56.858 ↗
40. Sustained release of venlafaxine from venlafaxine–montmorillonite–polyvinylpyrrolidone composites10.1016/j.clay.2010.11.013 ↗
41. Development and in vitro evaluation of a novel multiparticulate matrix controlled release formulation of theophylline10.3109/03639049509069244 ↗
42. A simple equation for the description of solute release III. Coupling of diffusion and relaxation10.1016/0378-5173(89)90306-2 ↗
43. Gelatin blended with nanoparticle cloisite30B (Mt) for control drug delivery of anticancer drug paclitaxel
44. Kinetics and metabolism of paracetamol and phenacetin10.1111/j.1365-2125.1980.tb01812.x ↗
45. Synthesis and characterization of new nitric oxide donor compounds based on theophylline and paracetamol
46. Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits10.1016/S0939-6411(03)00038-9 ↗
47. Biodegradable polymers and their layered silicate nanocomposites. In greening the 21st century materials world Progress
48. Effect of channeling agents on the release profile of theophylline from Methocel K4M based matrix tablets
49. Development of theophylline sustained release dosage form based on Kollidon Sr
50. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs10.1016/0168-3659(87)90034-4 ↗
51. Anti-inflammatory drug therapy in asthma10.1016/j.prrv.2009.06.007 ↗
52. Polyelectrolyte complex films derived from polyethyleneoxide–maleic acid copolymer and chitosan: preparation and characterization10.1002/mabi.200300110 ↗
53. Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis10.1016/j.pharmthera.2009.06.004 ↗
54. Influence of drug solubility, drug polymer ratio, nature of coexcipients and thermal treatment on drug release from carbopol
55. Preparation of a novel PEG-clay hybrid as a DDS material: dispersion stability and sustained release profiles10.1016/j.jconrel.2005.03.031 ↗
56. Comparative study on xanthan gum and hydroxypropylmethylcellulose as matrices for controlled-release drug delivery I. Compaction and in vitro drug release behaviour
57. In vitro drug release studies from a novel lyophilized nasal dosage form
58. Development of biomedical polymer-silicate nanocomposites: a materials science perspective10.3390/ma3052986 ↗
59. Biopolymer/montmorillonite nanocomposite: preparation, drug-controlled release property and cytotoxicity10.1088/0957-4484/19/6/065707 ↗
60. Low permeability biomedical polyurethane nanocomposites10.1002/jbm.a.10377 ↗
61. Controlled release of ofloxacin from chitosan–montmorillonite hydrogel10.1016/j.clay.2010.07.012 ↗
62. Synthesis and properties of polyimide-clay hybrid films10.1002/(SICI)1099-0518(199708)35:11<2289::AID-POLA20>3.0.CO;2-9 ↗
63. Study on ibuprofen/montmorillonite intercalation composites as drug release system10.1016/j.clay.2007.01.012 ↗